Parker Waichman Alonso LLP Supports FDA Safety Review of Yaz, Yasmin and Other Drospirenone-Containing Oral Contraceptives

Share Article

Continues to Call for the Removal of Yaz, Yasmin and other Drospirenone Birth Control Pills from the Market Due to their Association with Life-Threatening Blood Clots

Parker Waichman Alonso LLP, a national law firm dedicated to protecting the rights of injured victims, commends and fully supports the U.S. Food & Drug Administration's (FDA) decision to conduct a safety review of Yaz, Yasmin and other drospirenone contraceptives in light of recent studies indicating they pose a greater risk of life-threatening blood clots compared to other birth control pills. The firm continues to call on Bayer Corporation, the maker of Yaz and Yasmin, as well as the other manufacturers of drospirenone-containing birth control pills, to recall these products immediately until the FDA concludes its review due to the significant public health risks they may pose.

Drospirenone is a synthetic form of progestin which can elevate the body's potassium levels, leading to a condition called hyperkalemia in certain patients. Hyperkalemia may result in potentially serious heart and health problems. Adverse Events reported to the FDA involving Yaz, Yasmin and other drospirenone contraceptives include heart arrhythmias, electrolyte imbalance, hyponatremis, hyperkalemia, hyperkalemic arrhythmias, atrial fibrillation, tachycardia, bradycardia, myocardial infarction, stroke, transient ischemic attack, blood clots, embolisms, and sudden death. For more information regarding Yaz, Yasmin, legal matters, go to

On May 31, 2011, the FDA issued a Drug Safety Communication ( ) announcing that it would be reviewing the safety of Yaz, Yasmin and similar drospirenone contraceptives. The FDA’s announcement followed the publication of two studies in The British Medical Journal that reported a two- to three-fold greater risk of venous thromboembolic events in women using oral contraceptives containing drospirenone compared to those taking pills made with an alternative form of progestin. (Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 340:d2139. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340:d2151.)

In addition to Yaz and Yasmin, the FDA safety review also targets birth control pills sold under the names Beyaz, Gianvi, Loryna, Ocella, Safyral, Syeda, and Zarah.

According to the FDA, four earlier studies had been inconclusive as to whether the risk of blood clots was higher with pills containing drospirenone versus other forms of progestin. While two found no increased risk, two others published in 2009 did indicate that women using drospirenone-containing products faced a greater danger of experiencing a blood clot compared to those using other types of birth control pills.

While the FDA's safety review is a welcome development, it does not go far enough to protect young women from the significant health risks posed by drospirenone. For that reason, Parker Waichman Alonso LLP continues to call on Bayer Corporation, as well as the makers of other drospirenone contraceptives, to remove these products from the market immediately.

More than 6,000 lawsuits have been filed against Bayer Corporation and other makers of drospirenone-containing birth control pills by women across the United States claiming to have suffered strokes, pulmonary emboli, deep vein thrombosis, blood clots, gallbladder disease, and other serious injuries after taking these medications. Many of these lawsuits have been consolidated in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) currently pending in the United States District Court for the Southern District of Illinois. Andres F. Alonso, Esq., a partner with Parker Waichman Alonso LLP, is serving as a member of the Plaintiffs Steering Committee in that litigation.

Parker Waichman Alonso LLP continues to offer free legal evaluations to victims of drospirenone contraceptives, including Yaz and Yasmin. If you or a loved one suffered a heart attack, blood clot or stroke while taking one of these medications, please contact our office by visiting Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

About Parker Waichman Alonso LLP Parker Waichman Alonso LLP is a leading personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York, New Jersey, Florida, and Washington, D.C. For over 20 years, Parker Waichman Alonso LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective drugs, medical devices and other products.

For more information on Parker Waichman Alonso LLP, please visit or call 1-800-LAW-INFO (1-800-529-4636).

Contact:    Parker Waichman Alonso LLP                 
David B. Krangle, Esq.                
(800) LAW-INFO                                         
(800) 529-4636                            


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dave Krangle
Visit website